Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs.
Identifieur interne : 005947 ( Main/Exploration ); précédent : 005946; suivant : 005948Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs.
Auteurs : Mireille Gony [France] ; Maryse Lapeyre-Mestre ; Jean-Louis MontastrucSource :
- Clinical neuropharmacology [ 0362-5664 ]
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antidepressive Agents.
- chemical , therapeutic use : Antidepressive Agents.
- chemically induced : Basal Ganglia Diseases.
- complications : Depressive Disorder.
- drug therapy : Depressive Disorder, Parkinson Disease.
- Adverse Drug Reaction Reporting Systems, Humans, Risk Factors.
Abstract
To compare the risk of occurrence of "serious" extrapyramidal symptoms (EPS) between selective serotonin reuptake inhibitors and other antidepressant drugs in patients with Parkinson's disease (PD), the authors performed a retrospective study using the French Pharmacovigilance Database (i.e., the database recording all serious adverse drug reactions reported in France by physicians to the National French Pharmacovigilance Network). Patients with PD were identified from the case reports including at least one antiparkinsonian drug (except anticholinergics). The authors studied patients with PD exposed to at least one antidepressant (classified as imipraminics, selective serotonin reuptake inhibitors, or "other") drug. EPS were defined as aggravation of the parkinsonian symptoms. Of the76,640 case reports registered in the database between January 1, 1995, and December 31, 2000, 916 were identified as patients treated with at least one antiparkinsonian drug, including 199 treated with antidepressant drugs. Among them the authors found nine case reports of EPS (i.e., 4.5% of the patients with PD treated with at least one antidepressant). The odds ratio for EPS was 2.18 (0.47-11.35) for selective serotonin reuptake inhibitors, 1.17 (0.22-5.50) for imipraminics, and 0.74 (0.10-4.06) for other antidepressants. This study failed to find any significant difference in the occurrence of serious EPS according to the different classes of antidepressant drugs in patients with PD treated with dopaminergic antiparkinsonian drugs.
PubMed: 12782916
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001105
- to stream PubMed, to step Curation: 001064
- to stream PubMed, to step Checkpoint: 001064
- to stream Ncbi, to step Merge: 000337
- to stream Ncbi, to step Curation: 000337
- to stream Ncbi, to step Checkpoint: 000337
- to stream Main, to step Merge: 006484
- to stream Main, to step Curation: 005947
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs.</title>
<author><name sortKey="Gony, Mireille" sort="Gony, Mireille" uniqKey="Gony M" first="Mireille" last="Gony">Mireille Gony</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Pharmacologie Clinique, Unité de Pharmacoépidémilogie and Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémilogie et d'Informations sur le Médicament du Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Unité de Pharmacoépidémilogie and Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémilogie et d'Informations sur le Médicament du Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine de Toulouse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2003 May-Jun</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:12782916</idno>
<idno type="pmid">12782916</idno>
<idno type="wicri:Area/PubMed/Corpus">001105</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001105</idno>
<idno type="wicri:Area/PubMed/Curation">001064</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001064</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001064</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001064</idno>
<idno type="wicri:Area/Ncbi/Merge">000337</idno>
<idno type="wicri:Area/Ncbi/Curation">000337</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000337</idno>
<idno type="wicri:doubleKey">0362-5664::Gony M:risk:of:serious</idno>
<idno type="wicri:Area/Main/Merge">006484</idno>
<idno type="wicri:Area/Main/Curation">005947</idno>
<idno type="wicri:Area/Main/Exploration">005947</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs.</title>
<author><name sortKey="Gony, Mireille" sort="Gony, Mireille" uniqKey="Gony M" first="Mireille" last="Gony">Mireille Gony</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Pharmacologie Clinique, Unité de Pharmacoépidémilogie and Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémilogie et d'Informations sur le Médicament du Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Unité de Pharmacoépidémilogie and Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémilogie et d'Informations sur le Médicament du Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine de Toulouse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</analytic>
<series><title level="j">Clinical neuropharmacology</title>
<idno type="ISSN">0362-5664</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term>
<term>Antidepressive Agents (adverse effects)</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Basal Ganglia Diseases (chemically induced)</term>
<term>Depressive Disorder (complications)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Humans</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antidepressive Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Basal Ganglia Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term>
<term>Humans</term>
<term>Risk Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To compare the risk of occurrence of "serious" extrapyramidal symptoms (EPS) between selective serotonin reuptake inhibitors and other antidepressant drugs in patients with Parkinson's disease (PD), the authors performed a retrospective study using the French Pharmacovigilance Database (i.e., the database recording all serious adverse drug reactions reported in France by physicians to the National French Pharmacovigilance Network). Patients with PD were identified from the case reports including at least one antiparkinsonian drug (except anticholinergics). The authors studied patients with PD exposed to at least one antidepressant (classified as imipraminics, selective serotonin reuptake inhibitors, or "other") drug. EPS were defined as aggravation of the parkinsonian symptoms. Of the76,640 case reports registered in the database between January 1, 1995, and December 31, 2000, 916 were identified as patients treated with at least one antiparkinsonian drug, including 199 treated with antidepressant drugs. Among them the authors found nine case reports of EPS (i.e., 4.5% of the patients with PD treated with at least one antidepressant). The odds ratio for EPS was 2.18 (0.47-11.35) for selective serotonin reuptake inhibitors, 1.17 (0.22-5.50) for imipraminics, and 0.74 (0.10-4.06) for other antidepressants. This study failed to find any significant difference in the occurrence of serious EPS according to the different classes of antidepressant drugs in patients with PD treated with dopaminergic antiparkinsonian drugs.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
</list>
<tree><noCountry><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Gony, Mireille" sort="Gony, Mireille" uniqKey="Gony M" first="Mireille" last="Gony">Mireille Gony</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005947 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005947 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:12782916 |texte= Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12782916" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |